Current and future options for the treatment of serious infections due to carbapenem-resistant <i>Pseudomonas aeruginosa</i>
SUMMARY<i>Pseudomonas aeruginosa</i> is a frequent cause of hospital-acquired infections and is notable both for its virulence and its resistance to multiple antibiotics. In the absence of head-to-head clinical trials and availability of all potential options on a global basis, we have systematically analyzed potential antibiotics for carbapenem-resistant <i>P. aeruginosa</i>. Monotherapy with ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol, or high doses of ceftolozane-tazobactam is generally considered an acceptable option for serious infections due to carbapenem-resistant <i>P. aeruginosa</i>. The role of testing combinations of antimicrobial agents for <i>in vitro</i> susceptibility is uncertain, as is the administration of nebulized colistin or amikacin in patients with ventilator-associated pneumonia. With regard to new therapies, 10 clinical trials are underway or have been completed on bacteriophage therapy for <i>P. aeruginosa</i> infections. However, no phage options are yet widely approved for use. Other new options in clinical trials include beta-lactam antibiotics combined with new beta-lactamase inhibitors and antibody-based therapies.
Authors
- Keith S. Kaye (ORCID: https://orcid.org/0000-0003-2051-1732)
- David L. Paterson (ORCID: https://orcid.org/0000-0003-2079-4437)
- Juan Pablo Horcajada (ORCID: https://orcid.org/0000-0001-9873-5459)
- Cornelia B. Landersdorfer (ORCID: https://orcid.org/0000-0003-0928-4743)
- Dafna Yahav (ORCID: https://orcid.org/0000-0003-3181-9791)
- Andrea Lay‐Hoon Kwa (ORCID: https://orcid.org/0000-0001-8981-4411)
- Antonio Oliver (ORCID: https://orcid.org/0000-0001-9327-1894)
- Ana Cristina Gales (ORCID: https://orcid.org/0000-0003-0913-768X)
- Burcu Isler (ORCID: https://orcid.org/0000-0003-1362-2434)
- María Virginia Villegas (ORCID: https://orcid.org/0000-0003-1898-9067)
- Jason M. Pogue (ORCID: https://orcid.org/0000-0003-4780-6215)
- M. Montero (ORCID: https://orcid.org/0000-0001-5991-6804)
- Ryan K. Shields (ORCID: https://orcid.org/0000-0001-9794-5665)
Institutions
- Rutgers, The State University of New Jersey (US)
- The University of Queensland (AU)
- National University of Singapore (SG)
- Universitat Pompeu Fabra (ES)
- Universidad El Bosque (CO)
- University of Michigan (US)
- Sheba Medical Center (IL)
- Instituto de Salud Carlos III (ES)
- Princess Alexandra Hospital (AU)
- Johnson University (US)
- Rutgers Sexual and Reproductive Health and Rights (NL)
- Duke-NUS Medical School (SG)
- CNR de la Résistance aux Antibiotiques (FR)
- University of Pittsburgh Medical Center (US)
- Princess Alexandra Hospital (GB)
- National University Health System (SG)
- Hospital Universitario Son Espases (ES)
- Monash University (AU)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Clinical Microbiology Reviews
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1128/cmr.00233-24
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59